CARTITUDE-1: JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy for r/r multiple myeloma

Bookmark and Share
Published: 29 May 2020
Views: 126
Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA

Dr Jesus Berdeja speaks to ecancer online about his ASCO 2020 virtual presentation which discussed updates from the CARTITUDE-1 study.

JNJ-68284528 (JNJ-4528) is a chimeric antigen receptor T (CAR-T) cell therapy containing 2 BCMA-targeting single-domain antibodies.

He outlines the latest positive results, including a description of the toxicities.

Dr Berdeja discusses the next steps for the trial, and how it may be practice changing for multiple myeloma.